WATER SAFETY
the sampling strategy is designed properly. Sampling at the tap, first-draw and after flushing, gives an immediate picture of whether component leaching is contributing to risk. The audit work then breaks into three streams. First, a
desktop review of the asset register against installation dates and material specifications. Any pre-2000 brassware, any component without a current DZR certification, any fitting whose material data sheet cannot be located, goes onto the risk register. Second, a non-invasive survey of accessible plant rooms, risers, and outlets, prioritising areas where chemistry is most aggressive: softened systems, chemically dosed systems, long stagnation runs. Third, a targeted sampling programme on outlets serving the highest-risk patient groups. The replacement programme should be a phased prioritisation, not a brute-force project. Augmented care units come first: in these environments, the clinical case for a 5 µg/L working threshold is already unanswerable, despite the statutory limit. Paediatric and maternity areas follow next. General ward stock can then roll into planned refurbishment cycles as they arise, spreading the cost. The supply chain side of all this matters more than it usually gets credit for. A phased programme depends on the ability to specify, source and install matched components, with full material traceability, on a predictable schedule. When a hospital can prove the provenance of every fitting installed, with batch-level certification and a clear audit trail from manufacturer to fitted position, regulatory compliance becomes demonstrable rather than assumed. An audit like this is not a job that AI or asset management software can do alone. The audit requires engineers in plant rooms, surveyors on ward floors, and specifiers with hands-on knowledge of what the components actually are and how they will behave in the specific water chemistry of that trust.
Conclusion n The deadline is closer than you think
The deadline that matters for NHS lead compliance is not 2036. It was the day you specified the first component
that you intend to leave in a wall beyond 2032. Every project on a drawing board today is a 5 µg/L
project, whether or not the regulation has kicked in. The medical consensus has already moved. The DWI’s direction of travel is established. The asset lives we are designing against will outlast the current statutory limit by decades. The trusts that build around tomorrow’s threshold now will avoid the strip-out cycle. The trusts that defer it will inherit it – at five to ten times the cost – in the middle of clinical operations. Specify zero-lead alloys and lead-free DZR formulations certified to BS EN 1982, stainless press systems across high-risk wetted paths, and TBVs and TMVs properly specified to hold the HTM 04-01 operational envelope. When you support that with an auditable supply chain and a phased replacement programme built around clinical priority (rather than statutory minimum), compliance becomes something demonstrable rather than hopeful. It is simply what good specification looks like when you stop pretending 2036 is far away.
Every component should comply with the lower limit long before its design life ends.
September 2026 Health Estate Journal 53
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136
